By World Healthcare Journal-
A treatment developed by scientists at the Ichilov Medical Centre in Tel Aviv could be a breakthrough in the battle against Covid-19.
According to the findings of a recent Phase-I trial, researchers claim that the drug can help patients recover from Covid in just five days. Researchers told the Times of Israel that the treatment is a “huge breakthrough” and has the potential to have a great impact on coronavirus treatment.
Known as ‘EXO-C24’, the drug was successful in 29 out of 30 patients in the trial. In normal circumstances, most patients make a recovery from Covid in around three-four weeks time, but all 29 patients recovered in as little as five days, with only one taking longer to recover. All patients involved successfully recovered from the virus.
Previously developed as a cancer treatment less than a year ago, researchers repurposed the drug to treat Covid patients, which appears to have been successful so far. However, Phase-II and Phase-III trials will be necessary to properly evaluate the safety and efficacy of the drug in a larger population.
The treatment delivers a protein known as CD24 to the lungs, which works to prevent a cytokine storm - effectively sending the immune system into overdrive, which can lead to organ failure and death. If this treatment can help prevent a cytokine storm, we could see a drop in the severity of the disease - especially in at-risk groups.
“The preparation is directed straight to the heart of the storm - the lungs - so unlike other formulas, which selectively restrain a certain cytokine, or operate widely but cause many serious side effects, EXO-CD24 is administered locally, works broadly and without side effects,” says Professor Arber, one of the lead researchers on the project.
"Even if the vaccines do their job, and even if there aren't any new mutations, one way or another, the coronavirus will be staying with us. That's why we developed this special medication: EXO-CD24. This is unprecedented,” Prof. Arber added.
Now that the drug has displayed its efficacy in early trials, it will now move on to Phase-II and Phase-III trials to determine if the drug is suitable (and safe) for use in the population at large.
#whjnews #whjclinicaltrials #whjpharma #whjfabiansutch #coronavirus